| Drug Type Antibody fusion proteins | 
| Synonyms- | 
| Target | 
| Action modulators | 
| Mechanism IL-23 modulators(Interleukin-23 modulators), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Systemic Lupus Erythematosus | Preclinical | China  | 19 Apr 2024 | 






